Vetter News and Resources

Vetter, a contract development and manufacturing organisation (CDMO), has officially broken ground on a new clinical manufacturing site in Des Plaines, Illinois. The $285 million investment will support small-batch production for early-stage development and expand the company’s capacity to handle

Vetter, a global Contract Development and Manufacturing Organization (CDMO), has announced a significant expansion of its pharmaceutical materials warehouse in Ravensburg. With an investment exceeding €150 million, the expansion will increase the facility’s cool storage capacity by 16,000 pallet spaces,

Vetter a globally operating Contract Development and Manufacturing Organization (CDMO), has revealed plans for the upcoming launch of the V-OVS next, a next-generation version of its proprietary syringe closure system. The system is set for release in 2027 and aims

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the appointment of three senior leaders to its management team. Effective January 1, 2025, Henryk Badack, Titus Ottinger, and Carsten Press will join existing managing directors Thomas Otto

Vetter, a global Contract Development and Manufacturing Organization (CDMO), has successfully completed 100 clinical batches of liquid and lyophilized vials at its Rankweil, Austria facility. The site, which opened in 2021, supports the manufacturing and quality control of medicinal products

Vetter, a global Contract Development and Manufacturing Organization (CDMO), has announced plans to expand its Development Services site from Skokie, IL, to Des Plaines. This move is part of a strategic plan to further invest in its U.S. operations. In

Vetter has been honoured with the prestigious Best Managed Companies Award for the fifth consecutive year. This accolade, presented by Deloitte Private, Frankfurter Allgemeine Zeitung, the Federation of German Industries (BDI), and UBS, is a testament to the company’s commitment to

Vetter has also announced a significant financial milestone. With a result of €1,002 million in completed orders over the past financial year, Vetter has successfully surpassed the one billion sales threshold. In addition, the company has demonstrated its commitment to

Vetter, the Ravensburg, Germany-headquartered Contract Development and Manufacturing Organisation (CDMO), has announced successful commercial launch of eight customer products in 2023. The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases,